Department of Orthopedics, Taichung Veterans General Hospital, Taichung, Taiwan, ROC.
Center for Rare Disease and Hemophilia, Department of Paediatrics, Taichung Veterans General Hospital, Taichung, Taiwan, ROC; School of Medicine, China Medical University, Taichung, Taiwan, ROC.
J Chin Med Assoc. 2018 Oct;81(10):926-929. doi: 10.1016/j.jcma.2017.11.016. Epub 2018 Jul 13.
Perioperative management of persons with hemophilia (PWH) is a challenge for surgeons and hematologists. Reductions in mortality rate and complications have been achieved since the introduction of clotting factor concentrates (CFCs), which improve hemostatic control. However, there is no clear consensus on the optimal dosing of CFC administration. The aim of this study was to evaluate the outcome of PWH without inhibitors in patients undergoing invasive or surgical procedures. A total of 161 procedures, including 57 major and 104 minor ones were retrospectively reviewed. The characteristics of PWH, age at procedure, duration and total amount of CFC administration during the perioperative period, hemostatic adequacy, and complications were summarized. The study showed a low rate of bleeding (1.2%), infection (0%), thromboembolic event (0%), and inhibitor development (0%). The results revealed the doses and duration of CFC administration for several major and minor procedures which were capable of achieving excellent hemostatic control.
围手术期管理血友病患者(PWH)对外科医生和血液科医生来说是一个挑战。自从引入凝血因子浓缩物(CFC)以来,死亡率和并发症已经有所降低,这改善了止血控制。然而,对于 CFC 给药的最佳剂量尚未达成明确共识。本研究旨在评估无抑制剂的 PWH 患者在接受侵入性或手术治疗时的预后。共回顾了 161 例手术,包括 57 例大手术和 104 例小手术。总结了 PWH 的特征、手术时的年龄、围手术期 CFC 给药的持续时间和总量、止血效果和并发症。研究显示出血(1.2%)、感染(0%)、血栓栓塞事件(0%)和抑制剂发展(0%)的发生率较低。结果显示了几种大手术和小手术的 CFC 给药剂量和持续时间,这些剂量和持续时间能够实现极好的止血控制。